Sandbox:Haytham: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
{{Hepatitis A}}
{{CMG}}{{AE}}{{HL}}
{{CMG}}{{AE}}{{HL}}
w


*[[hepatitis A]]
;Durie-Salmon staging system
:*oral transmission
First published in 1975, the Durie-Salmon staging system <ref name="Salmon">Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. ''Cancer'' 1975;36:842–854. PMID 1182674.</ref> is still in use, but has largely been superseded by the simpler ISS:
::*infection
* stage 1: all of
** Hb > 10g/dL
** normal calcium
** Skeletal survey: normal or single plasmacytoma or osteoporosis
** Serum [[paraprotein]] level < 5 g/dL if IgG, < 3 g/dL if IgA
** Urinary [[light chain]] excretion < 4 g/24h
* stage 2: fulfilling the criteria of neither 1 nor 3
* stage 3: one or more of
** Hb < 8.5g/dL
** high calcium > 12mg/dL
** Skeletal survey: 3 or more lytic bone lesions
** Serum paraprotein >7g/dL if IgG, > 5 g/dL if IgA
** Urinary light chain excretion > 12g/24h
 
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Stage}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Hemoglobin level}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Calcium level}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Skeletal survey}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Serum paraprotein level}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Urinary light chain excretion}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
:Stage 1
| style="padding: 5px 5px; background: #F5F5F5;" |
*> 10g/dL
| style="padding: 5px 5px; background: #F5F5F5;" |
*8.5-10.2 mg/dL
| style="padding: 5px 5px; background: #F5F5F5;" |
*Normal or single plasmacytoma or osteoporosis
| style="padding: 5px 5px; background: #F5F5F5;" |
*< 5 g/dL if IgG or < 3 g/dL if IgA
| style="padding: 5px 5px; background: #F5F5F5;" |
*< 4 g/24h
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
:Stage 2
| style="padding: 5px 5px; background: #F5F5F5;" |
*8.5-10g/dL
| style="padding: 5px 5px; background: #F5F5F5;" |
*10.2-12 mg/dL
| style="padding: 5px 5px; background: #F5F5F5;" |
* fulfilling the criteria of neither 1 nor 3
| style="padding: 5px 5px; background: #F5F5F5;" |
*5-7 g/dL if IgG or 3-5 g/dL if IgA
| style="padding: 5px 5px; background: #F5F5F5;" |
*4-12 g/24h
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
:Stage 3
| style="padding: 5px 5px; background: #F5F5F5;" |
*< 8.5g/dL
| style="padding: 5px 5px; background: #F5F5F5;" |
*> 12mg/dL
| style="padding: 5px 5px; background: #F5F5F5;" |
*3 or more lytic bone lesions
| style="padding: 5px 5px; background: #F5F5F5;" |
*>7g/dL if IgG or > 5 g/dL if IgA
| style="padding: 5px 5px; background: #F5F5F5;" |
*> 12g/24h
|}

Revision as of 14:46, 19 September 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Durie-Salmon staging system

First published in 1975, the Durie-Salmon staging system [1] is still in use, but has largely been superseded by the simpler ISS:

  • stage 1: all of
    • Hb > 10g/dL
    • normal calcium
    • Skeletal survey: normal or single plasmacytoma or osteoporosis
    • Serum paraprotein level < 5 g/dL if IgG, < 3 g/dL if IgA
    • Urinary light chain excretion < 4 g/24h
  • stage 2: fulfilling the criteria of neither 1 nor 3
  • stage 3: one or more of
    • Hb < 8.5g/dL
    • high calcium > 12mg/dL
    • Skeletal survey: 3 or more lytic bone lesions
    • Serum paraprotein >7g/dL if IgG, > 5 g/dL if IgA
    • Urinary light chain excretion > 12g/24h
Stage Hemoglobin level Calcium level Skeletal survey Serum paraprotein level Urinary light chain excretion
Stage 1
  • > 10g/dL
  • 8.5-10.2 mg/dL
  • Normal or single plasmacytoma or osteoporosis
  • < 5 g/dL if IgG or < 3 g/dL if IgA
  • < 4 g/24h
Stage 2
  • 8.5-10g/dL
  • 10.2-12 mg/dL
  • fulfilling the criteria of neither 1 nor 3
  • 5-7 g/dL if IgG or 3-5 g/dL if IgA
  • 4-12 g/24h
Stage 3
  • < 8.5g/dL
  • > 12mg/dL
  • 3 or more lytic bone lesions
  • >7g/dL if IgG or > 5 g/dL if IgA
  • > 12g/24h
  1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842–854. PMID 1182674.